Not All JAK Inhibitors Carry the Same Shingles Risk in Rheumatoid Arthritis

For the millions of people living with rheumatoid arthritis (RA), JAK inhibitors — a class of oral medications that quiet the overactive immune response driving joint damage — have been a meaningful treatment advance. But these drugs come with a well-documented trade-off: they raise the risk of herpes zoster, the virus responsible for shingles, a painful rash that can cause lasting nerve pain and serious complications, particularly in older adults.

What has been less clear, until recently, is whether every JAK inhibitor in this drug class carries the same level of shingles risk — or whether some are meaningfully safer than others. That is the question the ANSWER cohort study set out to answer.

Why Shingles Is a Specific Concern With This Class of RA Drug

Shingles occurs when the varicella-zoster virus — the same virus that causes chickenpox — reactivates after lying dormant in nerve tissue, sometimes for decades. Most people who had chickenpox as children carry this virus silently for the rest of their lives. A healthy immune system keeps it in check. But when the immune system is suppressed, either by disease or medication, the virus can re-emerge as the painful, blistering rash known as shingles.

JAK inhibitors work by blocking specific signaling proteins (Janus kinases) that are involved in inflammatory and immune responses. This targeted suppression is what makes them effective against rheumatoid arthritis — but the same mechanism also reduces the body's ability to keep dormant viruses suppressed. As a result, shingles occurs more frequently in people taking JAK inhibitors than in those using older RA treatments such as conventional disease-modifying drugs.

Regulatory agencies in the United States and Europe have taken this risk seriously, adding warnings to JAK inhibitor labels and recommending shingles vaccination before starting these medications. Yet the question of how individual drugs within the JAK inhibitor class compare to each other has remained largely unanswered.

The Problem With Relying on Clinical Trial Safety Data Alone

Each JAK inhibitor — there are currently five approved for use in rheumatoid arthritis in Japan and other major markets — has been studied in its own set of clinical trials. Those trials were designed to test whether the drug works, with safety monitoring as a secondary focus. Because each trial enrolled different patient populations, followed participants for different lengths of time, and used different comparison groups, the shingles rates reported across those separate studies cannot be meaningfully compared against each other.

Think of it this way: if one drug's trial enrolled mostly younger patients and another's enrolled older patients — who have naturally higher shingles risk — any difference in shingles rates between the two trials could reflect the patient populations rather than the drugs themselves. Real-world studies, by contrast, can apply statistical methods to account for these differences and produce a more apples-to-apples comparison.

What the ANSWER Cohort Study Actually Did

The ANSWER cohort is a real-world observational registry drawn from rheumatology practices in Japan. Rather than assigning patients to treatments in a controlled experiment, the study observed patients who were already being treated with one of five different JAK inhibitors as part of their regular clinical care. This approach captures the messy, real-world reality of how these drugs are used — including in patients with other health conditions, at varying doses, and over varying durations — in a way that clinical trials typically cannot.

The researchers tracked how many patients in each treatment group developed herpes zoster over time. By comparing incidence rates across all five JAK inhibitors within the same study — using the same patient data, the same definitions, and the same analytical methods — the team was able to make direct, controlled comparisons that previous research had not been able to offer.

This type of head-to-head real-world evidence is particularly valuable for a condition like rheumatoid arthritis, where multiple drugs within the same class are available and physicians must choose among them based on incomplete comparative safety information.

Correcting a Common Misconception: 'Same Class' Does Not Mean 'Same Risk'

There is a widespread assumption — understandable but potentially misleading — that all drugs within a pharmacological class carry identical risks. With JAK inhibitors, this thinking goes: they all block JAK enzymes, so they should all suppress viral immunity to the same degree, producing the same shingles risk.

In reality, JAK inhibitors differ in which specific JAK enzyme subtypes they target and how selectively they act. The four major JAK subtypes — JAK1, JAK2, JAK3, and TYK2 — each play somewhat different roles in immune signaling. A drug that more strongly inhibits JAK3, for example, may have a different effect on antiviral immunity than one that primarily targets JAK1. Some JAK inhibitors are described as more 'selective' because they are designed to act on one or two subtypes rather than all of them.

These pharmacological differences mean that real-world risk comparisons — like the one the ANSWER cohort provides — are genuinely important. A class-wide safety warning is not the same as saying every drug in that class carries equal risk.

What This Research Means for People Managing Rheumatoid Arthritis

If you are currently taking a JAK inhibitor for rheumatoid arthritis, or if your doctor has suggested adding one to your treatment plan, this research matters to you in practical ways.

Shingles risk is not the only factor that determines which JAK inhibitor is right for you — disease severity, other health conditions, cost, and how well individual drugs work for your specific type of RA all matter. But shingles is a real and painful potential complication, and it can become a serious long-term problem in the form of postherpetic neuralgia, a nerve pain condition that can persist for months or years after the initial rash resolves.

Knowing that individual JAK inhibitors may carry meaningfully different shingles risk profiles gives you a more specific question to bring to your rheumatologist — particularly if you are older, have had shingles before, or have not yet received the shingles vaccine.